Treatment of Advanced Non–Small Cell Lung Cancer: From the Impossible to the Possible

Howard (Jack) West, MD


November 17, 2021

H. Jack West, MD, considers the transition from therapeutic bleakness for advanced non–small cell lung cancer in his early career to the current clinical setting in which patients have seen dramatic benefits for years at a time. By way of relating one of his first patient experiences with immunotherapy, Dr West suggests that therapies such as nivolumab have substantially altered the realm of treatment for advanced NSCLC, such that dramatically improved survival rates prompt the question as to whether what was once impossible is now possible.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.